NFKB1 and small cell lung carcinoma: Proteasome inhibition by carfilzomib interrupts cellular pathways integral to the survival of small cell lung cancer [2–4], namely the dysregulated apoptotic pathway involving activated nuclear factor-kB (NF-kB) [5].